deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00450944)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD22INHIBITOR
CD22 inhibitor
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01408160 | Phase 1 | Apr 1, 2013 | National Cancer Institute (NCI), Yeshiva University |
| NCT00450944 | Phase 1 | Nov 1, 2005 | Yeshiva University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yeshiva University | Academic/Hospital | 2 | 2 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1